PMC:7048229 / 5256-5399 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T22","span":{"begin":16,"end":19},"obj":"Body_part"},{"id":"T23","span":{"begin":24,"end":27},"obj":"Body_part"},{"id":"T24","span":{"begin":112,"end":122},"obj":"Body_part"}],"attributes":[{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma82739"}],"text":" anti-SARSr-CoV IgG and IgM ELISA kits were developed using SARSr-CoV Rp3 NP as antigen, which shared above 90% amino acid identity to all SARS"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T41","span":{"begin":74,"end":76},"obj":"http://purl.obolibrary.org/obo/CLO_0008192"}],"text":" anti-SARSr-CoV IgG and IgM ELISA kits were developed using SARSr-CoV Rp3 NP as antigen, which shared above 90% amino acid identity to all SARS"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T17","span":{"begin":74,"end":76},"obj":"Chemical"},{"id":"T20","span":{"begin":80,"end":87},"obj":"Chemical"},{"id":"T21","span":{"begin":112,"end":122},"obj":"Chemical"},{"id":"T22","span":{"begin":112,"end":117},"obj":"Chemical"},{"id":"T23","span":{"begin":118,"end":122},"obj":"Chemical"}],"attributes":[{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A18","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_53793"},{"id":"A19","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_73425"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_46882"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"}],"text":" anti-SARSr-CoV IgG and IgM ELISA kits were developed using SARSr-CoV Rp3 NP as antigen, which shared above 90% amino acid identity to all SARS"}

{"project":"LitCovid-PubTator","denotations":[{"id":"129","span":{"begin":60,"end":69},"obj":"Species"},{"id":"133","span":{"begin":6,"end":15},"obj":"Species"},{"id":"128","span":{"begin":70,"end":73},"obj":"Gene"}],"attributes":[{"id":"A128","pred":"tao:has_database_id","subj":"128","obj":"Gene:6103"},{"id":"A129","pred":"tao:has_database_id","subj":"129","obj":"Tax:694009"},{"id":"A133","pred":"tao:has_database_id","subj":"133","obj":"Tax:694009"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" anti-SARSr-CoV IgG and IgM ELISA kits were developed using SARSr-CoV Rp3 NP as antigen, which shared above 90% amino acid identity to all SARS"}